Early trial tests new DNA-Based COVID-19 vaccine
NCT ID NCT04673149
Summary
This study tested a new type of COVID-19 vaccine called GLS-5310, which uses DNA to teach the body's immune system to fight the virus. It involved 171 healthy adults and aimed to check if the vaccine was safe and if it triggered a protective immune response. The research was an early-phase trial to gather initial data on this experimental vaccine candidate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Korea University Guro Hospital
Seoul, 08308, South Korea
Conditions
Explore the condition pages connected to this study.